CureVac (NASDAQ:CVAC - Get Free Report) shares fell 6.1% during trading on Wednesday . The stock traded as low as $3.27 and last traded at $3.31. 525,492 shares traded hands during trading, a decline of 47% from the average session volume of 990,520 shares. The stock had previously closed at $3.52.
Analysts Set New Price Targets
Separately, JMP Securities restated a "market outperform" rating and set a $16.00 target price on shares of CureVac in a research report on Friday, February 14th.
Read Our Latest Research Report on CureVac
CureVac Price Performance
The company has a current ratio of 6.20, a quick ratio of 6.19 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $738.80 million, a PE ratio of 6.00 and a beta of 2.51. The stock's 50-day moving average is $3.63 and its two-hundred day moving average is $3.21.
Institutional Trading of CureVac
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Private Advisor Group LLC bought a new position in CureVac in the 3rd quarter worth about $30,000. Integrated Wealth Concepts LLC bought a new position in shares of CureVac during the third quarter valued at approximately $35,000. International Assets Investment Management LLC acquired a new stake in CureVac in the third quarter valued at approximately $35,000. Two Sigma Advisers LP acquired a new stake in CureVac in the fourth quarter valued at approximately $48,000. Finally, Jump Financial LLC acquired a new stake in CureVac in the fourth quarter valued at approximately $55,000. 17.26% of the stock is owned by hedge funds and other institutional investors.
About CureVac
(
Get Free Report)
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.
Read More
Before you consider CureVac, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CureVac wasn't on the list.
While CureVac currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
